Krystal Biotech Inc. has announced a conference call scheduled for July 24, 2025, at 4:30pm ET to discuss the results of the PEARL-2 study, the KB304 clinical development program, and Jeune's pipeline product candidates. The call will also cover the strategic vision for Jeune, a wholly owned subsidiary of Krystal Biotech. The discussion will highlight the positive safety and efficacy results from the Phase 1 study of KB304 for moderate to severe wrinkles of the décolleté. Investors and the general public can access the live webcast at https://www.webcaster4.com/Webcast/Page/3018/52758, and a replay will be available on the Krystal website for those unable to attend the live session.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Krystal Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001711279-25-000069), on July 24, 2025, and is solely responsible for the information contained therein.